New Delhi: Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating `diabetic dyslipidemeia` for launch, the company said in a filing to BSE.Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."
Repeated ceasefire violations; when will Pakistan stop?
Imran Khan adamant on PM Sharif`s resignation
No Leader of Opposition: SC asks Modi govt to clear stand
Jaipur: Air India flight makes emergency landing due to technical fault